SIGA Technologies main competitors are Salix Pharmaceuticals, Revance Therapeutics, and Gilead Sciences.
Competitor Summary. See how SIGA Technologies compares to its main competitors:
|Company||Founding Date||Zippia Score||Headquarters||# of Locations||Revenue||Employees|
|New York, NY||1||$86.7M||43|
|Ann Arbor, MI||1||$78.4M||218|
|San Diego, CA||1||$1.5B||400|
|New York, NY||2||$68.8M||34|
|Foster City, CA||9||$27.3B||11,800|
|Thousand Oaks, CA||9||$26.3B||22,000|
|South San Francisco, CA||3||$42.7M||160|
|Los Angeles, CA||1||$228.0M||265|
|Palo Alto, CA||1||$82.4M||100|
|San Francisco, CA||2||$92.1M||718|
|Parsippany-Troy Hills, NJ||4||$666.8M||750|
|Company||Highest Salary||Hourly Salary|
Hoffmann-LA Roche Inc
Human Genome Sciences
|Company||White||Hispanic or Latino||Black or African American||Asian||Unknown||Diversity Score|
Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.
Nick Leschly has served as our chief bluebird since September 2010. Formerly, Nick was a partner and founding member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for VELCADE. Nick also founded and served as chief executive officer of MedXtend Corporation. He received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO) and Synlogic Therapeutics.
Sheldon Koenig joined Portola in 2019 and is responsible for leading the Company’s commercial operations. Prior to joining Portola, Mr. Koenig was senior vice president and head of the cardiovascular franchise for Sanofi, where he led the US business operations and global product launches in more than 20 countries. Previously, he served as vice president and global brand leader for the cardiovascular division of Merck & Co, Inc. where, for more than 25 years, he took on roles of increasing responsibility within the company’s cardiovascular and thrombosis franchises. He has significant overall experience in primary care, specialist, and hospital markets, as well as business development and licensing. Mr. Koenig holds a B.S. from Drexel University and an M.B.A. from Monmouth University.
A world-renowned physician and entrepreneur, Lindsay Rosenwald has served the medical profession for over 30 years. In that time, Lindsay Rosenwald has achieved success in a wide array of services including venture capital, direct investing, asset management and investment banking within the field of life sciences and biotechnology. Most notably, Lindsay Rosenwald has been a significant creator of development-stage biotechnology companies. Throughout his professional career, Lindsay Rosenwald has overseen the development of more than 100 licensed clinical-stage medicines. A number of these drugs have earned approval from the U.S. Food and Drug Administration and foreign countries. One medicine in particular was to treat acute promyelocytic leukemia, which has since cured several thousands of incurable patients in the past decade. Under the guidance of Lindsay Rosenwald, the medicine has marked a dramatic shift in how the disease will be treated in the future. Another cancer medicine formulated under the leadership of Lindsay Rosenwald is a prostate cancer drug called abiraterone acetate. The company led by Lindsay Rosenwald that developed this drug became the first of its kind to be acquired for around $1 billion after the completion of just a single phase 2 study when Johnson & Johnson took ownership of the company in a short-term merger. Other drugs approved during the career of Lindsay Rosenwald include drugs approved for treatment of diseases such as schizophrenia, influenza, fibromyalgia, infant respiratory distress syndrome, and obesity. After graduating from southeast Pennsylvania’s Abington Senior High School in 1973, Lindsay Rosenwald matriculated at Pennsylvania State University. There, Lindsay Rosenwald received a bachelor’s degree in finance and economics, graduating a member of Beta Gamma Sigma, an international honor society.
Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.
Howard Robin joined Nektar Therapeutics in January 2007. He has more than 25 years of successful biopharmaceutical experience managing clinical development and commercial operations. Most recently, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, asthma, respiratory syncytial virus (RSV) and Huntington's disease. During his tenure at Sirna, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck for $1.1 billion. Prior to Sirna, Mr. Robin spent 20 years at Berlex Laboratories, the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG. From 1991 to 2001, he served as corporate vice president and general manager of their U.S. Therapeutics division and was responsible for the development of drugs, such as Betaseron® (Interferon beta-1b) for multiple sclerosis and Fludara® (fludarabine phosphate) for chronic lymphocytic leukemia, generating annual global sales in excess of $800 million. He also served as a member of the Executive Committee. Prior to that, he was vice president of Finance and Business Development and CFO of Berlex. Earlier in his career, Mr. Robin was a senior associate with Arthur Andersen and Co. Mr. Robin serves as a director of the Biotechnology Industry Organization, the world's largest biotechnology industry trade organization. Mr. Robin holds a B.S. in Accounting and Finance from Fairleigh Dickinson University in New Jersey and serves as a member of its Board of Trustees.
Auerbach is the Founder, President, and CEO of Puma Biotechnology, a company dedicated to in-licensing and developing drugs for the treatment of cancer. Previously, he founded Cougar Biotechnology and served as the company's President and CEO until the company's acquisition by Johnson & Johnson in 2009. Following the acquisition, Mr. Auerbach served as the Co-Chairman of the Integration Steering Committee at Cougar that provided leadership and oversight for the development and global commercialization of Cougar's lead product candidate, abiraterone acetate, for the treatment of advanced prostate cancer. Prior to founding Cougar, Mr. Auerbach was a Vice President, Senior Research Analyst at Wells Fargo Securities, where he was responsible for research coverage of small- and middle- capitalization biotechnology companies, with a focus on oncology. He had primary responsibility for technical, scientific, and clinical due diligence as well as selection of biotechnology companies followed by the company. Prior to that, Mr. Auerbach was a Vice President, Research Analyst at the Seidler Companies, where he was responsible for research coverage of small-capitalization biotechnology companies. Previous to his work as a biotechnology analyst, Mr. Auerbach worked for Diagnostic Products Corporation, where he designed and implemented clinical trials in the field of oncology. Mr. Auerbach received a BS in Biomedical Engineering from Boston University and an MS in Biomedical Engineering from the University of Southern California.
Experienced MedTech Executive with 25+ years of experience including roles as a senior executive, CEO (public and private companies), Founder/entrepreneur, Venture Capitalist and Board Member/Executive Chairman/Chairman. Served as Chairman, President and Chief Executive Officer of ZELTIQ Aesthetics (ZLTQ) from April of 2012 until the Company's acquisition by Allergan for $2.5B in April of 2017. Initially, I joined ZELTIQ in 2009 as Executive Chairman and as a member of the Board of Directors. Currently, I am a Managing Director at RWI Ventures, serve as Chairman of the Board for ULab, HintMD and Arrinex and am a board member at Glaukos (GKOS) and Revance (RVNC). Prior to this, I served on the boards of several private companies, held operating roles in large, public companies and venture-backed start-ups including US Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic) where I was the founder and CEO. I received my B.A. from the University of Notre Dame (1987) and am a named inventor on 17 patent applications.